Horizon Space Acquisition I Corp. (HSPOF) Form 8-K — Oct 13, 2026
$HSPOFForm 8-KItems 1.01, 7.01, 9.01Filed Oct 13, 2026, 8:30 AM ET0001929980-26-000542Original filing
Horizon Space Acquisition I Corp. (HSPO) entered into a Business Combination Agreement on October 12, 2026 with ArcheNova Biotech Corp. and ArcheNova Technology Co., Ltd, the future public holding company. The deal values ArcheNova Biotech at a $2.0 billion equity value with an exchange ratio based on a $10.00 per share reference price.
Key figures
- Deal Value Usd
- 2000000000
- Offering Price
- 10
- Rights conversion
- 1 Acquiror Right = 1/10 Acquiror Ordinary Share
- Warrant conversion
- 1 Acquiror Warrant = 1 PubCo Warrant
- Company equity value
- $2.0 billion
- Exchange ratio basis
- $2.0 billion / $10.00 per share / Company Ordinary Shares outstanding
- Pubco post deal board
- 2 Company-nominated directors, 1 Acquiror-nominated director
- Company shares outstanding
- 5000000
- Acquiror warrant exercise price
- $11.50
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.